Main Menu

Epizyme, Inc.


Rigrodsky Law, P.A. is investigating Epizyme, Inc. (“Epizyme”) regarding possible breaches of fiduciary duties and other violations of law related to Epizyme’s agreement to be acquired by Ipsen S.A. Under the terms of the agreement, Epizyme’s shareholders will receive $1.45 in cash and one contingent value right (CVR) of $1.00 for each share of Epizyme common stock they own.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 11/26/2022

* Indicates a required field.

Back to Page